Topiramate
Product Images NDC 68071-4793

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68071-4793). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4793 3)

Topiramate 25mg tablets bottle label from NuCare Pharmaceuticals, Inc. The label indicates a package of 30 round-shaped white/off-white tablets, each containing 25mg of topiramate. Tablets are debossed with 'ZD 16' on one side. The label includes the product number P1808030, a warning to keep out of reach of children, storage instructions at 68-77°F, and notes that the product is Rx only.*

FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 01)

Chemical structure of topiramate, showing its molecular arrangement with functional groups including sulfonamide and multiple ether rings.*

FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 02)

Line graph showing cumulative seizure rate over time (days) comparing two doses of topiramate: 50 mg/day and 400 mg/day. The y-axis represents cumulative rate to first seizure, and the x-axis shows time up to 500 days. The graph indicates a statistically significant difference between the two dosing groups (p=0.0002).*

FDA Label Image

Topiramate Tablets Usp (Af70d392 31a6 40bb 8f0a Ab51a70067fb 03)

A bar graph comparing change from baseline to double-blind phase in average monthly migraine period rate with standard error for placebo, topiramate 50 mg/day, 100 mg/day, and 200 mg/day. Data from two studies are shown with separate bars, illustrating greater reduction in migraine rates with increased topiramate doses compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.